Erasca (ERAS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Erasca (ERAS) is Neutral.

The composite score behind that read is -0.03, weighing +0.24 of bullish evidence against -0.23 bearish.

Erasca last closed at $14.72, -0.14% on the session.

Against the IVW growth benchmark the position is -1.06% over the forecast window.

The read is built from 12 underlying insights — 6 bullish and 6 bearish.

Agreement across those insights is 50%.

9 graded predictions for ERAS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Erasca in the 13th percentile on return on equity, where 100 is best.

Erasca is classified under Health Care / Biotechnology, with a market capitalisation of $5.16B.

StockMap tracks Erasca as the 53rd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Erasca ranks 48th of 344 in the group, against a group median of -0.21.